Prostate cancer
Prof Chris Parker presents the RADICALS-HD trial which will ensure clinicians can better tailor treatment for prostate cancer patients following surgery and help facilitate important discussions.
The trial showed encouraging results for radiotherapy without hormone therapy so some patients, concerned with upsetting side effects of hormone therapy, can be reassured this treatment alone is a good option.
For other patients, at higher risk of their cancer returning, two years of hormone therapy is more effective than six months of treatment.
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Choosing Wisely in radiology Tanzania